Sargramostim is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) used as a hematopoietic growth factor. It is a glycosylated recombinant protein produced using a Saccharomyces cerevisiae expression system. Sargramostim contains 127 amino acid residues and differs from native human GM-CSF by substitution of leucine for arginine at position 23.
Sargramostim stimulates hematopoietic progenitor cells and supports the production and differentiation of granulocyte and macrophage lineages. Its biological activity is evaluated using validated cell-based potency methods rather than relying solely on conventional small-molecule chemical assay techniques.
Sargramostim is a single-chain glycosylated protein. Because glycosylation produces multiple molecular species, its apparent molecular mass is approximately 15.5, 16.8 and 19.5 kDa. The protein moiety has a calculated molecular weight of 14,414 Da.
The recombinant protein is produced in yeast and contains the characteristic R23L sequence substitution. Protein identity and quality are therefore evaluated using protein-specific analytical techniques such as peptide mapping, chromatographic characterization and biological activity testing.
Sargramostim is used as a GM-CSF therapy to stimulate myeloid recovery and hematopoietic progenitor cell activity. Current U.S. Leukine indications include selected applications involving acute myeloid leukemia, hematopoietic progenitor-cell mobilization and recovery following bone marrow or peripheral blood progenitor-cell transplantation.
Sargramostim has also been developed for additional administration routes, including inhalation formulations in Japan. PMDA describes the inhalation product as recombinant Sargramostim with a molecular weight of approximately 17,000 Da.
Sargramostim requires biologic-specific quality control rather than a conventional small-molecule API specification. USP defines biological potency at NLT 73.0% and NMT 146.0% of the labeled potency, corresponding to 5.6 million USP Sargramostim Units/mg of protein. USP also identifies host-cell DNA and host-cell protein as process-specific impurities controlled using validated methods.
Protein identity, chromatographic purity, glycosylation profile, protein content and biological potency are important quality attributes for Sargramostim.
Sargramostim is a complex recombinant biologic and should be evaluated using validated protein-specific analytical procedures. Manufacturing and quality documentation can include identity testing, purity characterization, protein concentration, glycosylation characterization, host-cell impurity assessment, residual DNA testing, endotoxin testing and biological potency evaluation as applicable to the manufacturing process.
Sargramostim drug substance requires controlled handling appropriate for a recombinant protein. Final formulation storage conditions depend on the dosage form and validated stability program. Finished Leukine presentations include both liquid and lyophilized formulations.
Technical documentation for Sargramostim may include Certificate of Analysis, batch analytical results, manufacturing information, analytical methods, stability information, biological potency data, impurity-control information and applicable regulatory documentation.
Sargramostim is a well-characterized recombinant GM-CSF with an established USP monograph and defined biological potency requirements. Its manufacture requires specialized recombinant-protein production, purification and analytical characterization capabilities rather than conventional chemical synthesis alone.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.1% |
| Individual Impurity | NMT 0.10% |
| Total Impurities | NMT 0.50% |